Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer

Asian Journal of Andrology

Volumn 11, Issue 1, 2009, Pages 131-137

  Hsu, Chao Yu ^a   Joniau, Steven ^a   Oyen, Raymond ^a   Roskams, Tania ^a   Poppel, Hein Van ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHARLSON SCORE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME; AGE; DISEASE FREE SURVIVAL; HOSPITALIZATION; KAPLAN MEIER METHOD; LIFE EXPECTANCY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR;

ADULT; AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIERS ESTIMATE; LIFE EXPECTANCY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX;

EID: 69449107374     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2008.35     Document Type: Article

References (26)

1. Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HGW, et al Results of Radical prostatectomy in men with locally advanced prostate cancer: Multi-institution pooled analysis. Eur Urol 1997; 32: 385-90.
2. Van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998; 160: 1392-7.
3. Martinez de la Riva SI, Lopez-Tomasety JB, Dominguez RM, Cruz EA, Blanco PS. Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up. Arch Esp Urol 2004; 57: 679-92.
4. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU International 2005; 95: 751-6.
5. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome for clinical unilateral T3a prostate cancer: A single-institution experience. Eur Urol 2007; 51: 121-9.
6. Carver BS, Bianco FJ, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176: 564-8.
7. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-83.
9. Hsu CY, Joniau S, Van Poppel H. Radical prostatectomy for locally advanced prostate cancer: Technical aspects of radical prostatectomy. EAU Update Series 2005; 3: 90-7.
10. Sobin LH, Wittekind C. TNM Classification of prostate cancer. 6th edn. New York: Wiley-Liss, 2002; p184-7.
11. Heidenberg HB, Moul JW, Mostofi FK, McLeod DG. Clinically detected carcinoma of the prostate treated by radical prostatetomy in a 29-year-old man. J Urol 1994; 152: 966-7.
12. Gronberg H, Damber JE, Jonsson H, Lenner P. Patient age as a prognostic factors in prostate cancer. J Urol 1994; 152: 892-5.
13. Gronberg H, Damber L, Jonson H, Damber JE. Prostate cancer mortality in northern Sweden with special reference to tumor grade and patient age. Urology 1997; 49: 374-8.
14. Herold DM, Hanlon AL, Movsav B, Hanks GE. Age-related prostate cancer metastases. Urology 1998: 52:985-990.
15. Carter HB, Epstein JI, Partin AW. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999; 53: 126-30.
16. Ruska KM, Partin AW, Epstein JI, Kahane H. Adenocarcinoma of the prostate in men younger than 40 years of age: Diagnosis and treatment with emphasis on radical prostatectomy findings. Urology 1999; 53: 1179-83.
17. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 2003; 62: 86-92.
18. Smith CV, Bauer JJ, Connelly RR, Seay T, Kane C, et al. Prostate cancer in men age 50 years or younger: A review of the department of defense center for prostate disease research multicenter prostate cancer database. J Urol 2000; 164: 1964-7.
19. Obek C, Lai S, Sadek S, Civantos F, Sloway MS. Age as a prognostic factor for disease recurrence after radical prostatectomy. Urology 1999; 54: 533-8.
20. Freedland SJ, Presti JC, Kane CJ, Aroson WJ, Terris MK, et al. Do younger men have better biochemical outcomes after radical prostatectomy. Urology 2004; 63: 518-22.
21. Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, et al. Impact of patient age at treatment on outcome following radical retropublic prostatectomy for prostate cancer. J Urol 2006; 175(3 Pt 1): 952-7.
22. Kastner C, Armitage J, Kimble A, Rawal J, Carter PG, et al. The Charlson comorbidity score: A superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer Prostatic Dis 2006; 9: 270-4.
23. Froehner M, Koch R, Litz R, Heller A, Oehlschlaeger S, et al. Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology 2003; 62: 698-701.
24. Froehner M, Koch R, Litz R, Oehlschlaeger S, Wirth MP. Which conditions contributing to the Charlson score predict survival after redical prostatectomy? J Urol 2004; 172 (2 Pt 1): 697-9.
25. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-101.
26. Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, et al. Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004; 171: 1513-9.